Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06759701 | Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study | recruiting | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07468708 | The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer | recruiting | Early Phase 1 | 10 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 |
| clinicaltrials |
| NCT07542379 | The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer | recruiting | Early Phase 1 | 13 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07609225 | Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy | not yet recruiting | Early Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07798778 | Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer(SRT-017-001) | recruiting | Early Phase 1 | 18 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | not yet recruiting | Early Phase 1 | 40 | Lumina Pharmaceuticals IncINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07674771 | Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery(RIPCORD) | not yet recruiting | Early Phase 1 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07727473 | Preoperative Semaglutide Prior to Radical Prostatectomy | not yet recruiting | Early Phase 1 | 20 | Banner HealthOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05530655 | A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer | recruiting | Early Phase 1 | 30 | University of RochesterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06228404 | Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC | active not recruiting | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04857502 | 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer | recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05852041 | rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance | recruiting | Early Phase 1 | 40 | Northwestern UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06813898 | An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial | recruiting | Early Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07608848 | First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer(DOTA-STR-17126) | recruiting | Early Phase 1 | 20 | Integrated Haematology and Oncology NetworkOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05045066 | Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients | recruiting | Early Phase 1 | 220 | Mayo ClinicOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05477823 | Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer | active not recruiting | Early Phase 1 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05515978 | Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients(PragMet) | recruiting | Early Phase 1 | 100 | University of Colorado, DenverOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07240857 | A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer | enrolling by invitation | Early Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05851365 | Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer | active not recruiting | Early Phase 1 | 1 | Robert Flavell, MD, PhDOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02526368 | Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer | recruiting | Early Phase 1 | 80 | Ivan de Kouchkovsky, MDOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05047965 | An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer | active not recruiting | Early Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07516704 | Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study | not yet recruiting | Early Phase 1 | 94 | Zhongda HospitalOTHER | 0 | Apr 8, 2026 | clinicaltrials |
| NCT07164027 | Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial | recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03334500 | Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer | active not recruiting | Early Phase 1 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03861676 | Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT | recruiting | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05683964 | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | active not recruiting | Early Phase 1 | 9 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05160597 | Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy | active not recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06408298 | HCQ in Resectable Localized Prostate Cancer | recruiting | Early Phase 1 | 20 | Lionel.D.Lewis, MDOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07381582 | Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(161Tb-LNC1011) | not yet recruiting | Early Phase 1 | 15 | Peking Union Medical College HospitalOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT03511196 | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | active not recruiting | Early Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05603559 | 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer | recruiting | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05802121 | Akkermansia Muciniphilia and Metabolic Side Effects of ADT | recruiting | Early Phase 1 | 30 | Western UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT03392181 | PET/MRI for the Staging of Newly Diagnosed Prostate Cancer | active not recruiting | Early Phase 1 | 48 | Northwestern UniversityOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06864572 | [68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer | enrolling by invitation | Early Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06756334 | Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis | recruiting | Early Phase 1 | 30 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06612580 | 68Ga-AAZTA-NI-093 PET/CT: First-in-human Study | recruiting | Early Phase 1 | 10 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06546527 | Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） | not yet recruiting | Early Phase 1 | 12 | Peking University First HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT05549024 | 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients | recruiting | Early Phase 1 | 90 | Peking Union Medical College HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials